Palm Therapeutics
5 employees on LinkedIn · 1 known investors
Palm Therapeutics develops palmitoylation-targeted drugs using its proprietary PalmReader screening platform to identify novel therapeutic molecules. The company focuses on modulating protein palmitoylation, a post-translational modification involved in multiple disease pathways.
Founders & leadership
AR
Andrew RuddCofounder & CEO
Investors · 1
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $467.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $585.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Palm Therapeutics do?
- Palm Therapeutics develops palmitoylation-targeted drugs using its proprietary PalmReader screening platform to identify novel therapeutic molecules. The company focuses on modulating protein palmitoylation, a post-translational modification involved in multiple disease pathways.
- Who founded Palm Therapeutics?
- Palm Therapeutics was founded by Andrew Rudd.
- Who are Palm Therapeutics's investors?
- Palm Therapeutics's investors include Tachyon Ventures.